Charles River Laboratories International, Inc. (CRL)
$
157.12
-0.37 (-0.24%)
Key metrics
Financial statements
Free cash flow per share
11.1143
Market cap
7.7 Billion
Price to sales ratio
1.9229
Debt to equity
0.9347
Current ratio
1.4332
Income quality
-28.1442
Average inventory
284.4 Million
ROE
-0.0089
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Charles River Laboratories International, Inc. is a prominent non-clinical contract research organization that offers a range of services, including drug discovery, non-clinical development, and safety testing across various global markets, including the United States, Europe, Canada, and the Asia Pacific. The cost of revenue for the company is $2,718,168,000.00 showcasing its production and operational expenses that support its comprehensive service offerings. With an operating income ratio of 0.06 the company's operational profitability margin reflects its ability to maintain efficiency in its business activities. Additionally, the company incurred an interest expense of $126,288,000.00 which indicates its debt servicing obligations and financial commitments. The total costs and expenses for the company amount to $3,822,642,000.00 reflecting its overall spending in pursuit of excellence in research services. Furthermore, the gross profit ratio is 0.33 which assesses the efficiency of the company's production and sales operations, underscoring its strategic management practices and financial health. Moving forward, the stock is reasonably priced at $154.40 appealing to a broad range of investors seeking opportunities in the market. The stock has an average trading volume of 1,558,447.00 indicating moderate liquidity, which is favorable for both institutional and retail investors. With a mid-range market capitalization of $7,717,058,784.00 the company is recognized as a steady performer within the competitive landscape. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative approaches and extensive portfolio of services. Moreover, it belongs to the Healthcare sector, driving innovation and growth that enhance its reputation and stability in the industry as it responds to evolving market needs.
Is Charles River Laboratories International, Inc. (CRL) a good investment?
Investing in Charles River Laboratories International, Inc. (CRL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Charles River Laboratories International, Inc. (CRL)'s stock forecast?
Analysts predict Charles River Laboratories International, Inc. stock to fluctuate between $91.86 (low) and $254.15 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Charles River Laboratories International, Inc.'s market capitalization?
As of 2025-07-03, Charles River Laboratories International, Inc.'s market cap is $7,717,058,784, based on 49,115,700 outstanding shares.
How does Charles River Laboratories International, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Charles River Laboratories International, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Charles River Laboratories International, Inc. (CRL) stock?
To buy Charles River Laboratories International, Inc. (CRL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRL. Place an order (Market, Limit, etc.).
What is the best time to invest in Charles River Laboratories International, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Charles River Laboratories International, Inc. perform in the last earnings report?
Revenue: $4,049,989,000 | EPS: $0.20 | Growth: -97.84%.
Where can I find Charles River Laboratories International, Inc.'s investor relations reports?
Visit https://www.criver.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Charles River Laboratories International, Inc.?
You can explore historical data from here
What is the all-time high and low for Charles River Laboratories International, Inc. stock?
All-time high: $460.21 (2021-09-24) | All-time low: $91.86 (2025-04-11).
What are the key trends affecting Charles River Laboratories International, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
zacks.com
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
zacks.com
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
cnbc.com
The firm has three possible paths toward value creation at the drug development company.
investopedia.com
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.
seekingalpha.com
Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Dave Windley - Jefferies Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Kyle Crews - UBS Patrick Donnelly - Citi Casey Woodring - JPMorgan Charles Rhyee - TD Cowen Tejas Savant - Morgan Stanley Rob Cottrell - Cleveland Research Operator Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter 2025 Earnings Conference Call. This call is being recorded.
benzinga.com
Charles River Laboratories International Inc CRL stock is trading higher on Wednesday after the company released better than expected first-quarter 2025 earnings.
reuters.com
Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board.
reuters.com
Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment Management to add four new directors to its board and launch a strategic review of the business, two sources familiar with the matter said.
seekingalpha.com
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data. Aldeyra already has two trials with data expected in Q2 2025, aiming for NDA resubmission by mid-2025. Reproxalap targets upstream inflammation, offering rapid symptom relief in a large market, with a risk-adjusted U.S. revenue potential of $216 million annually.
See all news
